Press release
Tay-Sachs Disease Pipeline 2025: Pioneering Clinical Developments by 4+ Global Leaders - DelveInsight | Featuring Sanofi Genzyme, IntraBio
Tay-Sachs Disease Pipeline 2025
As Tay-Sachs Disease continues to impact populations worldwide and is associated with comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is an increasing need for safer and more effective treatments. DelveInsight reports that the Tay-Sachs Disease pipeline includes 4+ pharmaceutical and biotech companies actively developing over 5 therapeutic candidates for the condition. These therapies are in various stages of clinical and preclinical development, highlighting significant innovation and dedication to tackling this critical public health challenge.
DelveInsight's "Tay-Sachs Disease Pipeline Insight 2025" offers a comprehensive strategic analysis of the R&D landscape. The report details clinical trial progress, emerging therapies, mechanisms of action, competitive dynamics, and key company initiatives, serving as an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving Tay-Sachs Disease therapeutics market and its future advancements.
Explore the Cutting-Edge Landscape of Tay-Sachs Disease Drug Development @ https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Tay-Sachs Disease Pipeline Report
*
DelveInsight's Tay-Sachs Disease pipeline report highlights a dynamic landscape with 4+ active companies developing over 5 therapeutic candidates for Tay-Sachs Disease.
*
AXO-AAV-GM2, a gene therapy developed by Axovant Gene Therapies, employs adeno-associated viral vectors to deliver functional HEXA and HEXB genes to the central nervous system. In 2020, the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for AXO-AAV-GM2, enabling the start of a registrational study for Tay-Sachs and Sandhoff diseases. The therapy has also received Orphan Drug and Rare Pediatric Disease designations from the FDA.
*
Leading Tay-Sachs Disease companies such as Sanofi Genzyme, IntraBio, and others are actively pursuing new treatments to enhance the therapeutic landscape. Promising pipeline candidates include Venglustat, IB1001, and additional therapies in development.
Tay-Sachs Disease Overview:
Tay-Sachs disease is a serious inherited disorder that primarily affects the nervous system and results from a deficiency of the enzyme beta-hexosaminidase A, caused by mutations in the HEXA gene on chromosome 15. This enzyme is essential for breaking down GM2 ganglioside, a lipid, within lysosomes. In its absence, GM2 accumulates in nerve cells, causing progressive neurological damage. Tay-Sachs is inherited in an autosomal recessive pattern, meaning a child must inherit a defective gene from both parents to develop the disease, while carriers with only one mutated gene usually remain symptom-free. Because of its effects on lysosomal function and GM2 buildup, Tay-Sachs is classified as both a lysosomal storage disorder and a GM2-gangliosidosis.
The disease is divided into three main forms based on when symptoms appear: infantile, juvenile, and late-onset. The infantile form is the most severe, typically appearing around six months of age, with symptoms including loss of motor skills, exaggerated startle response, seizures, hearing and vision loss, and a characteristic "cherry-red" spot on the retina. Neurological decline progresses rapidly, and affected children rarely survive beyond early childhood. Juvenile Tay-Sachs emerges in early childhood or adolescence and is characterized by coordination difficulties, speech impairment, and cognitive decline. While its progression is slower than the infantile form, it remains a serious, often fatal condition by early adulthood.
Download the Tay-Sachs Disease sample report to know in detail about the Tay-Sachs Disease treatment market [https://www.delveinsight.com/sample-request/tay-sachs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Tay-Sachs Disease Pipeline Analysis
The Tay-Sachs Disease pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Tay-Sachs Disease Market.
*
Categorizes Tay-Sachs Disease therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Tay-Sachs Disease drugs under development based on:
*
Stage of development
*
Tay-Sachs Disease Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Tay-Sachs Disease Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Tay-Sachs Disease Licensing agreements
*
Funding and investment activities supporting future Tay-Sachs Disease market advancement.
Unlock key insights into emerging Tay-Sachs Disease therapies and market strategies here: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Tay-Sachs Disease Emerging Drugs
*
Venglustat: Sanofi Genzyme
Venglustat is an investigational oral therapy aimed at slowing disease progression by reducing the accumulation of glycosphingolipids (GSLs). It is still in clinical trials and has not received approval from any regulatory authority. The U.S. FDA has granted Venglustat Fast Track designation for Gaucher disease type 3, Fabry disease, and GM2 gangliosidosis. Furthermore, it has obtained Orphan Drug Designation in both the U.S. and Europe for GM2 gangliosidosis. Currently, Venglustat is in Phase III clinical development for Tay-Sachs disease.
*
IB1001: IntraBio
IB1001 is a novel oral therapy developed by IntraBio, a U.S.-based biopharmaceutical company focused on therapies for rare and common neurological disorders. The drug, a modified amino acid (N-acetyl-L-leucine), employs a specialized transport mechanism to reach target tissues, including crossing the blood-brain barrier. This enables it to restore normal lysosomal and mitochondrial function, reduce neuroinflammation, and stabilize neuronal membrane potential and intracellular ion balance via calcium channels. IB1001 is currently being evaluated in Phase II clinical trials for Tay-Sachs disease.
Tay-Sachs Disease Pipeline Therapeutic Assessment
Tay-Sachs Disease Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Tay-Sachs Disease By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Tay-Sachs Disease Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Tay-Sachs Disease Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Tay-Sachs Disease therapies and key Tay-Sachs Disease companies [https://www.delveinsight.com/sample-request/tay-sachs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Tay-Sachs Disease Current Treatment Patterns
4. Tay-Sachs Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Tay-Sachs Disease Late-Stage Products (Phase-III)
7. Tay-Sachs Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Tay-Sachs Disease Discontinued Products
13. Tay-Sachs Disease Product Profiles
14. Tay-Sachs Disease Key Companies
15. Tay-Sachs Disease Key Products
16. Dormant and Discontinued Products
17. Tay-Sachs Disease Unmet Needs
18. Tay-Sachs Disease Future Perspectives
19. Tay-Sachs Disease Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Tay-Sachs Disease pipeline reports offerings [https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=taysachs-disease-pipeline-2025-pioneering-clinical-developments-by-4-global-leaders-delveinsight-featuring-sanofi-genzyme-intrabio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tay-Sachs Disease Pipeline 2025: Pioneering Clinical Developments by 4+ Global Leaders - DelveInsight | Featuring Sanofi Genzyme, IntraBio here
News-ID: 4198423 • Views: …
More Releases from ABNewswire
98% Consistency, 0 Staff: Anno Robot Redefines Airport Coffee in 60 Countries
As millions of travellers rush through terminals worldwide, one constant complaint has finally been solved: bad airport coffee served slowly by exhausted staff. Shenzhen-based Anno Robot [https://www.coffeerobotsanno.com/] has quietly eliminated both problems with fully robotic kiosks that deliver 98% brew-to-brew consistency and require zero human baristas. By November 2025, these AI-powered stations are operating in airports and high-traffic hubs across more than 60 countries, marking a turning point for the…
FAXVIN Unveils Enhanced CarRank, a 0-100 Single-Score Summary That Makes Used-Ca …
Updated methodology brings additional partner data and refined signal weighting so shoppers and dealers can rank and compare vehicles in seconds.
WALNUT, Calif. - Nov. 19, 2025 - FAXVIN today announced a significant update to CarRank, its 0-100 vehicle-history metric designed to help shoppers and dealers compare used cars at a glance. The latest release incorporates additional data sources and methodology refinements that improve how risk signals are weighted across title…
Global Pro AV Market Surges Toward USD 127.31 Billion by 2030, Led by Sony, Sams …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
According to Arizton research, the global pro AV market [https://www.arizton.com/market-reports/pro-av-market] was valued at USD 90.00 billion in 2024 and is projected to reach USD 127.31 billion by 2030, growing at a CAGR of 5.95% during the forecast period.
Explore the Full Market Insights: https://www.arizton.com/market-reports/pro-av-market
Report Summary:
Market Size (2030): USD 127.31 Billion
Market Size (2024): USD 90.00 Billion
CAGR (2024-2030): 5.95%
Historic…
Redway Power Launches High-Capacity 51.2V 420Ah Lithium Forklift Battery for Nex …
Redway Power, a leading OEM lithium battery manufacturer, proudly announces the launch of its latest innovation: the 51.2V 420Ah Lithium Forklift Battery [https://www.redwaypower.com/product/48v-420ah-forklift-lithium-battery/]. Designed for modern industrial operations, this next-generation battery combines high capacity, advanced safety features, and customizable OEM/ODM solutions to revolutionize warehouse productivity and material handling efficiency.
Introducing Next-Generation Power for Forklifts
The new 51.2V 420Ah battery is engineered to deliver exceptional energy efficiency and durability. With a nominal energy…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
